Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV/Flu-01E Vaccine for RSV Prevention in Older Adults
NCT06890429Phase 2Completed
- Sponsor
- Smorodintsev Research Institute of Influenza
- Start
- Dec 2023
- Primary completion
- Jan 2024
- Modality
- Viral Vector Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RSV/Flu-01E with Placebo (2 arms). Primary endpoints: Level of RSV F antigen-specific cytokine producing CD4+ and CD8+ T-cells at Day 28 and Level of the RSV F antigen-specific Th1/Th2 cytokine release in whole blood assay at Day 28. Started Dec 2023; status: completed.
02
Drugs
RSV/Flu-01E
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06890429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890429.